Iron-dependent lysosomal dysfunction mediated by a natural product hybrid

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Cellular Imaging

Background:

• Artesumycin is a hybrid molecule merging marmycin A and artemisinin.
• It was engineered to target cancer cell lysosomes by combining lysosomotropic and iron-reactive properties.

Purpose of the Study:

• To investigate artesumycin's efficacy in inhibiting cancer cell proliferation.
• To explore its mechanism of action, focusing on iron dependency and lysosomal targeting.
• To assess its utility as a fluorescent probe for visualizing lysosomal dysfunction.

Main Methods:

• Synthesis of artesumycin, a fluorescent hybrid of marmycin A and artemisinin.
• In vitro assays to evaluate cancer cell proliferation inhibition.
• Iron-dependency studies using redox-active iron(II).
• Fluorescence microscopy to visualize cellular uptake and lysosomal localization.

Main Results:

• Artesumycin demonstrated iron-dependent inhibition of cancer cell proliferation.
• The molecule underwent chemical fragmentation in vitro in the presence of iron(II).
• Fluorescence microscopy confirmed selective targeting of lysosomes by artesumycin.

Conclusions:

• Artesumycin is an effective inhibitor of cancer cell proliferation, acting through an iron-dependent mechanism.
• Its ability to selectively target and visualize lysosomes offers a novel strategy for studying and potentially treating cancer.
• This fluorescent, iron-reactive probe provides a powerful tool for initiating and observing lysosomal dysfunction in human cancer cells.